Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ABBV CLS 579

Next Previous
Drug Profile

ABBV CLS 579

Alternative Names: ABBV-CLS-579

Latest Information Update: 31 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AbbVie
  • Developer AbbVie; Calico
  • Class Antineoplastics; Immunotherapies
  • Mechanism of Action Protein tyrosine phosphatase non-receptor type 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 21 Aug 2025 AbbVie in collaboration with Calico Life Sciences completes phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Combination therapy, Second-line therapy or greater) in Taiwan, Spain, South Korea, France, Israel, Japan, USA (PO) (NCT04417465) (EudraCT2020-000639-28)
  • 21 Aug 2025 AbbVie in collaboration with Calico Life Sciences completes phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in Taiwan, Spain, South Korea, France, Israel, Japan, USA (PO) (NCT04417465) (EudraCT2020-000639-28)
  • 27 Nov 2023 Phase-I development is ongoing Japan, Israel and USA (AbbVie pipeline, November 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top